CONFERENCE DAY ONE
8:00 am Digital Networking Room Opens
8:25 am Chair’s Opening Remarks
Developing Innovative Combination Strategies to Unlock Novel Applications of Hippo- Targeted Drugs
8:30 am Per Aspera Ad Astra: The Potential of Hippo Pathway inhibition as a Mono- & Combination Therapy Concept
9:00 am Panel Discussion: Advancing Hippo Pathway Combination Strategies: Exploring Current & Future Cross-Pathway Opportunities
9:45 am Morning Break & Virtual Networking
Tackling Resistance Mechanisms Driven by the Hippo Pathway to Effectively Develop Combination Strategies Against MAPK & EGFR Cancers
10:30 am Determining New Roles of the Hippo Pathway in Driving Cancer Formation, Progression & Adaptive Resistance to Inform Combination Strategies
11:00 am Exploring Resistance Mechanisms in MAPK-Addicted Cancers: YAP Upregulation, Immune Suppression, & Innovative Combination Strategies for Hippo Pathway Targeted Drugs
11:30 am Drug Persistence Versus Drug Resistance to KRAS G12C Inhibitors & implications for YAP/TAZ Targeted Drugs
12:00 pm Lunch Break & Virtual Networking
Developing Innovative Drugs Against YAP & TEAD Through Cutting-Edge Discovery Platforms to Hit the Pathway at Multiple Nodes
Chair: Melanie Frigault, Consultant, Translational Medicine, Vincerx Pharma